ClinicalTrials.gg
CompletedNCT00343200Updated Feb 1, 2021

A Study Of The Safety and Efficacy Of Viagra In Men With Erectile Dysfunction Who Do Not Self Identify.

A Phase 4 interventional study of Placebo and Viagra (sildenafil citrate) in Impotence, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 48 sites in United States. Open to male participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2021-02-01.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
371
Allocation
Randomized
Ages
30 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing sildenafil in Erectile Dysfunction — 1 open to participants now, 1 under way, 1 of them phase 3. sildenafil · Erectile Dysfunction.

Enrollment
6th of 50
371 · median 108
Started
2006
with 2 others
Phase 4
30 of 50
none open now
Registered
17th of 50
by date
Lead sponsor
23 of 50
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 50 studies testing sildenafil in Erectile Dysfunction, this one is the 6th largest by enrollment, is one of 3 that started in 2006, is one of 30 in phase 4, and was the 17th registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

1 of the 50 studies testing sildenafil in Erectile Dysfunction is open now. Recruiting first, the newest first:

About sildenafil

sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 30 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing sildenafil in Erectile Dysfunction, or all of them as a file.
02

Study summary

To compare the efficacy and safety of Viagra (sildenafil citrate) vs. placebo for the treatment of men with ED and at least 1 prespecified risk factor who do not self identify as having ED.

03

Conditions studied

  • Impotence

Browse trials for

04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men who do not identify as having ED with documented ED
  • Men 30 years of age and older
  • At least one prespecified risk factor for ED

Exclusion criteria

Exclusion Criteria:

  • Subjects currently prescribed, taking and/or likely to be treated with nitrates or nitric oxide donors in any form on either a regular or intermittent basis
  • Subjects with a known history of retinitis pigmentosa.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
371 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    Sildenafil

    Drug: Viagra (sildenafil citrate)

Interventions

  • DrugPlacebo

    Placebo tablet orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period, for a total of 8 weeks (DB phase). In 4-week OL phase, subjects received sildenafil 50 mg or 100mg orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period.

  • Sildenafil 50 mg or 100mg orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period, for a total of 12 weeks (8-week DB phase and 4-week OL phase).

06

What researchers measure

Primary outcomes

  1. To determine the change from baseline in Erectile Function (EF) domain of International Index of Erectile Function (IIEF).

    Time frame: Week 8

Secondary outcomes

  1. Other questionnaires and variables such as IIEF, SEAR, GEAQ, SEX-Q, QEQ, EDITS, SEP, Event Log, Erection Hardness Grading Score, and Morisky Compliance.

    Time frame: Weeks 8 and 12

  2. Safety and Tolerability

    Time frame: up to 12 Weeks

07

Study locations

48 sites
  • Pfizer Investigational Site
    Huntsville, Alabama 35801, United States
  • Pfizer Investigational Site
    Mesa, Arizona 85213, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85023, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85051, United States
  • Pfizer Investigational Site
    Anaheim, California 92801, United States
  • Pfizer Investigational Site
    Beverly Hills, California 90211, United States
  • Pfizer Investigational Site
    Huntington Beach, California 92648, United States
  • Pfizer Investigational Site
    San Diego, California 92123, United States
  • Pfizer Investigational Site
    Santa Rosa, California 95405, United States
  • Pfizer Investigational Site
    Aurora, Colorado 80012, United States
  • Pfizer Investigational Site
    Colorado Springs, Colorado 80904, United States
  • Pfizer Investigational Site
    Denver, Colorado 80212, United States
  • Pfizer Investigational Site
    Avon, Connecticut 06001, United States
  • Pfizer Investigational Site
    Manchester, Connecticut 06040, United States
  • Pfizer Investigational Site
    Wilmington, Delaware 19801, United States
  • Pfizer Investigational Site
    Washington, District of Columbia 20010, United States
  • Pfizer Investigational Site
    Hollywood, Florida 33021, United States
  • Pfizer Investigational Site
    Jacksonville, Florida 32216, United States
  • Pfizer Investigational Site
    Ocala, Florida 34474, United States
  • Pfizer Investigational Site
    Pembroke Pines, Florida 33024, United States
  • Pfizer Investigational Site
    Tampa, Florida 33607, United States
  • Pfizer Investigational Site
    Peoria, Illinois 61602, United States
  • Pfizer Investigational Site
    Fort Wayne, Indiana 46825, United States
  • Pfizer Investigational Site
    Arkansas City, Kansas 67005, United States
  • Pfizer Investigational Site
    Newton, Kansas 67114, United States
  • Pfizer Investigational Site
    Overland Park, Kansas 66215, United States
  • Pfizer Investigational Site
    Wichita, Kansas 67205, United States
  • Pfizer Investigational Site
    Wichita, Kansas 67207, United States
  • Pfizer Investigational Site
    Livonia, Michigan 48152, United States
  • Pfizer Investigational Site
    Edina, Minnesota 55435, United States
  • Pfizer Investigational Site
    Las Vegas, Nevada 89146, United States
  • Pfizer Investigational Site
    Binghamton, New York 13901, United States
  • Pfizer Investigational Site
    Endwell, New York 13760, United States
  • Pfizer Investigational Site
    New York, New York 10016, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio 45236, United States
  • Pfizer Investigational Site
    Mogadore, Ohio 44260, United States
  • Pfizer Investigational Site
    Oklahoma City, Oklahoma 73116, United States
  • Pfizer Investigational Site
    Tulsa, Oklahoma 74136, United States
  • Pfizer Investigational Site
    Greer, South Carolina 29651, United States
  • Pfizer Investigational Site
    Simpsonville, South Carolina 29681, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37203, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78229, United States
  • Pfizer Investigational Site
    Salt Lake City, Utah 84109, United States
  • Pfizer Investigational Site
    Salt Lake City, Utah 84121, United States
  • Pfizer Investigational Site
    Richmond, Virginia 23294, United States
  • Pfizer Investigational Site
    Spokane, Washington 99207, United States
  • Pfizer Investigational Site
    Tacoma, Washington 98405, United States
  • Pfizer Investigational Site
    Oregon, Wisconsin 53575, United States
08

References and documents

Publications

  • Cappelleri JC, Chambers R. Addressing Bias in Responder Analysis of Patient-Reported Outcomes. Ther Innov Regul Sci. 2021 Sep;55(5):989-1000. doi: 10.1007/s43441-021-00298-5. Epub 2021 May 27. PubMed 34046875 ↗
  • Kaminetsky JC, Stecher V, Tseng LJ. Quality of erections by age group in men with erectile dysfunction. Int J Clin Pract. 2017 Oct;71(10). doi: 10.1111/ijcp.12976. Epub 2017 Sep 11. PubMed 28892218 ↗
  • Shabsigh R, Kaufman J, Magee M, Creanga D, Russell D, Budhwani M. Lack of awareness of erectile dysfunction in many men with risk factors for erectile dysfunction. BMC Urol. 2010 Nov 5;10:18. doi: 10.1186/1471-2490-10-18. PubMed 21054874 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2006 and a completion of Sep 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2006
First posted
Jun 22, 2006
Start
Jul 2006
CompletionActual
Sep 2007
Last update
Feb 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00343200
Responsible party
Sponsor
First posted
Jun 22, 2006
Start date
Jul 2006
Completion
Sep 2007
Last update
Feb 1, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion